IDH2
Isocitrate dehydrogenase [NADP], mitochondrial
As of the edition of 20 October 2026, IDH2 (isocitrate dehydrogenase [NADP], mitochondrial, UniProt P48735) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48735
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 13
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Nervous system; Digestive system; Hormones; Skin and connective tissue
- Registered trials of its drugs
- 68
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Enasidenib | Marketed | Phase 3 | Ends 2034 |
| Vorasidenib | Marketed | Phase 3 | Ends 2039 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Servier | Route B |
The other 1 company at IDH2
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at IDH2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.